PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31102492-7 2020 RESULTS: In parallel with the suppression of interleukin-6 and tumor necrosis factor-alpha production in resting and lipopolysaccharide-stimulated macrophages, metformin could induce an increase in Dicer and most miRNAs. Metformin 160-169 tumor necrosis factor Mus musculus 63-90 31002870-5 2019 The results showed that metformin pretreatment increased the phosphorylation of HDAC5 at serine 498, leading to the upregulation of KLF2, and eliminated lipopolysaccharide (LPS) and tumor necrosis factor (TNF )-induced upregulation of vascular cell adhesion molecule 1 (VCAM1). Metformin 24-33 tumor necrosis factor Mus musculus 182-203 31319131-6 2019 We found that the metformin pretreatment alleviated the lung injury and decreased the levels of TNF-a, IL-1beta and IL-6 in the bronchoalveolar lavage fluid (BALF) and in lung tissues, as well as the levels of NLRP3, NLRC4 and cleaved caspase-1 associated with LPS-induced ALI in old mice. Metformin 18-27 tumor necrosis factor Mus musculus 96-101 31002870-5 2019 The results showed that metformin pretreatment increased the phosphorylation of HDAC5 at serine 498, leading to the upregulation of KLF2, and eliminated lipopolysaccharide (LPS) and tumor necrosis factor (TNF )-induced upregulation of vascular cell adhesion molecule 1 (VCAM1). Metformin 24-33 tumor necrosis factor Mus musculus 207-210 30935688-7 2019 The current results showed that metformin activated autophagy and decreased the mRNA expressions of inflammatory cytokines, IL-1beta, IL-6, and TNF-alpha via inhibition of the STAT3 mRNA and protein expression. Metformin 32-41 tumor necrosis factor Mus musculus 144-153 30116349-8 2018 Furthermore, secretion of TNF-alpha, IL-1alpha, M-CSF and TCA-3 into the conditioned media was significantly decreased by metformin (5 and 10 mM; P<0.05). Metformin 122-131 tumor necrosis factor Mus musculus 26-35 30242842-3 2018 Metformin at relatively low doses was shown to suppress FcepsilonR1-mediated degranulation, IL-13, TNF-alpha and sphingosine-1-phosphate (S1P) secretion in murine bone marrow-derived mast cells (BMMCs). Metformin 0-9 tumor necrosis factor Mus musculus 99-108 28935544-10 2018 In vivo, we discovered that metformin not only decreased the serum level of the pro-inflammatory cytokines IL-6 and TNF-alpha but also lowered the expression of the M1 macrophage markers CD11c and MCP-1 in adipose tissue. Metformin 28-37 tumor necrosis factor Mus musculus 116-125 29859833-4 2018 The results indicated that treatment with metformin suppressed LPS-induced upregulation of IL-6 and TNF-alpha, alleviated pulmonary histological abnormalities, improved the survival rate of LPS-challenged mice. Metformin 42-51 tumor necrosis factor Mus musculus 100-109 28935544-11 2018 In vitro, metformin reduced the secretion of IL-6 and TNF-alpha in palmitate-stimulated RAW264.7 macrophages, while compound C treatment blocked the effect of metformin. Metformin 10-19 tumor necrosis factor Mus musculus 54-63 29554661-6 2018 RESULTS: The contents of pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor (TNF)-alpha were inhibited by ALK, metformin or fasudil in diabetic db/db mice. Metformin 143-152 tumor necrosis factor Mus musculus 85-119 28827783-4 2017 The CCDC3 expression is markedly reduced in TAp63-null mouse embryonic fibroblasts and brown adipose tissues and by tumor necrosis factor alpha that reduces p63 transcriptional activity, but induced by metformin, an anti-diabetic drug that activates p63. Metformin 202-211 tumor necrosis factor Mus musculus 116-143 28921708-4 2017 Both scopoletin and metformin lowered blood glucose and HbA1c , serum ALT, TNF-alpha and IL-6 levels, glucose intolerance, and hepatic lipid accumulation compared with the diabetic control group. Metformin 20-29 tumor necrosis factor Mus musculus 75-84 28921708-5 2017 Scopoletin or metformin down-regulated hepatic gene expression of triglyceride (Pparg, Plpp2, and Dgat2) and cholesterol (Hmgcr) synthesis as well as inflammation (Tlr4, Myd88, Nfkb1, Tnfa, and Il6), while it up-regulated Cyp7a1 gene. Metformin 14-23 tumor necrosis factor Mus musculus 184-188 28410530-3 2017 In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice. Metformin 51-60 tumor necrosis factor Mus musculus 163-172 28559290-7 2017 Treatment of adipocytes with metformin decreased the effects of lipopolysaccharide on inducing the phosphorylation states of JNK p46 and on increasing the mRNA levels of IL-1beta and TNFalpha. Metformin 29-38 tumor necrosis factor Mus musculus 183-191 28439456-14 2017 ELISA assay revealed decreased levels of inflammatory response marker IL-1beta and TNF-alpha in the pancreatic tissues following metformin treatment. Metformin 129-138 tumor necrosis factor Mus musculus 83-92 28410530-3 2017 In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice. Metformin 51-60 tumor necrosis factor Mus musculus 134-161 28002460-9 2016 In addition, metformin supplementation in IL10KO mice suppressed macrophage pro-inflammatory activity as indicated by reduced M1 macrophage abundance and decreased pro-inflammatory cytokine IL-1beta, TNF-alpha and IFN-gamma expressions. Metformin 13-22 tumor necrosis factor Mus musculus 200-209 26276089-7 2015 Adriamycin or metformin alone or in combination induced significant increase in the survival rate, tissue catalase, reduced glutathione and tissue caspase 3 activity with significant decrease in tumor volume, tissue malondialdehyde, tissue sphingosine kinase 1 activity and tumor necrosis factor alpha and alleviated the histopathological changes with significant increase in Trp53 expression and apoptotic index compared to SEC group. Metformin 14-23 tumor necrosis factor Mus musculus 274-301 27059094-7 2016 The increased gene expressions of TNF-alpha, IL-6, monocyte chemoattractant protein 1 and F4/80 were also down-regulated by metformin and resveratrol. Metformin 124-133 tumor necrosis factor Mus musculus 34-43 27252117-13 2016 The tissue levels of IL-6, TNF-alpha and CRP were markedly decreased by 21-day treatment with metformin (200 mg/kg/d) (p < 0.001). Metformin 94-103 tumor necrosis factor Mus musculus 27-36 24770553-4 2015 Metformin + Con A-treated mice had elevated serum levels of pro-inflammatory cytokines TNF-alpha and IFN-gamma, accompanied by a massive mononuclear cell infiltration in the liver. Metformin 0-9 tumor necrosis factor Mus musculus 87-96 26265045-3 2015 In the present study, the potential modulatory effects of metformin on TNF-alpha-dependent apoptotic liver damage was investigated in mice with TNF-alpha/d-galactosamine (D-Gal)-induced liver injury. Metformin 58-67 tumor necrosis factor Mus musculus 71-80 26265045-3 2015 In the present study, the potential modulatory effects of metformin on TNF-alpha-dependent apoptotic liver damage was investigated in mice with TNF-alpha/d-galactosamine (D-Gal)-induced liver injury. Metformin 58-67 tumor necrosis factor Mus musculus 144-153 26265045-7 2015 These data indicated that metformin effectively alleviated TNF-alpha/D-Gal-induced apoptotic liver injury and these beneficial effects were at least partially mediated by AMPK. Metformin 26-35 tumor necrosis factor Mus musculus 59-68 25951664-8 2014 Metformin improved metabolic disorders, upregulated activity of renal AMPK, diminished the expression of renal SREBP-1c, TNF-alpha, NOX4 mRNA, decreased accumulation of renal lipids, and prevened renal injury. Metformin 0-9 tumor necrosis factor Mus musculus 121-130 25472042-17 2014 Expanding on this we determine that activation of AMPK via metformin reduces lipid droplet accumulation, presumably by eliminating the inhibitory effects of TNF-alpha, resulting in normalisation of fatty acid oxidation and HADH2 (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit) activity. Metformin 59-68 tumor necrosis factor Mus musculus 157-166 24009539-0 2013 Metformin Down-regulates TNF-alpha Secretion via Suppression of Scavenger Receptors in Macrophages. Metformin 0-9 tumor necrosis factor Mus musculus 25-34 24973221-3 2014 Metformin inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner and in parallel induction of activating transcription factor-3 (ATF-3), a transcription factor and member of the cAMP-responsive element-binding protein family. Metformin 0-9 tumor necrosis factor Mus musculus 46-73 24973221-3 2014 Metformin inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner and in parallel induction of activating transcription factor-3 (ATF-3), a transcription factor and member of the cAMP-responsive element-binding protein family. Metformin 0-9 tumor necrosis factor Mus musculus 75-84 24973221-6 2014 ChIP-PCR analysis revealed that LPS-induced NF-kappaB enrichments on the promoters of IL-6 and TNF-alpha were replaced by ATF-3 upon metformin treatment. Metformin 133-142 tumor necrosis factor Mus musculus 95-104 24973221-8 2014 Oral administration of metformin to either mice with LPS-induced endotoxemia or ob/ob mice lowered the plasma and tissue levels of TNF-alpha and IL-6 and increased ATF-3 expression in spleen and lungs. Metformin 23-32 tumor necrosis factor Mus musculus 131-140 24204674-10 2013 In obese mice, greater levels of eotaxin, TNF-alpha and NOx, together with increased iNOS protein expression were observed, all of which were normalized by metformin. Metformin 156-165 tumor necrosis factor Mus musculus 42-51 24204674-14 2013 In conclusion, metformin inhibits the TNF-alpha-induced inflammatory signaling and NF-kappaB-mediated iNOS expression in lung tissue of obese mice. Metformin 15-24 tumor necrosis factor Mus musculus 38-47 25315906-11 2014 In addition, metformin activated AMPK phosphorylation, inhibited NF-kappaB activation, down-regulated cytokine (IL-1beta, IL-6, TNF-alpha) and ICAM-1 expression following tMCAO (P < 0.05). Metformin 13-22 tumor necrosis factor Mus musculus 128-137 24009539-5 2013 Metformin reduced the production of NO, PGE2 and pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) through down-regulation of NF-kappaB translocation in macrophages in a dose-dependent manner. Metformin 0-9 tumor necrosis factor Mus musculus 96-105 24009539-7 2013 Also, metformin suppressed secretion of TNF-alpha and reduced the protein and mRNA expression of TNF-alpha in obese mice as well as in macrophages. Metformin 6-15 tumor necrosis factor Mus musculus 40-49 24009539-7 2013 Also, metformin suppressed secretion of TNF-alpha and reduced the protein and mRNA expression of TNF-alpha in obese mice as well as in macrophages. Metformin 6-15 tumor necrosis factor Mus musculus 97-106 24009539-9 2013 These results suggest that metformin may attenuate inflammatory responses by suppressing the production of TNF-alpha and the expressions of scavenger receptors. Metformin 27-36 tumor necrosis factor Mus musculus 107-116 21091653-6 2011 KEY RESULTS: Both pre- and post-treatment with metformin significantly improved survival of animals during lethal endotoxaemia (survival rate was monitored up to 2 weeks), decreased serum levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta, HMGB1 expression and myeloperoxidase activity in lungs. Metformin 47-56 tumor necrosis factor Mus musculus 228-237 22330083-5 2012 Metformin also markedly reduced hepatic TNF-alpha mRNA content and blood TNF-alpha level. Metformin 0-9 tumor necrosis factor Mus musculus 40-49 22330083-5 2012 Metformin also markedly reduced hepatic TNF-alpha mRNA content and blood TNF-alpha level. Metformin 0-9 tumor necrosis factor Mus musculus 73-82 23557965-8 2013 RESULTS: Metformin attenuated both arthritis scores and bone destruction in CAIA mice, decreased the serum levels of the pro-inflammatory cytokines, TNF-alpha and IL-1, and reduced the number of RORgammat+CD4+ T cells in the ALNs. Metformin 9-18 tumor necrosis factor Mus musculus 149-158 16514202-9 2006 Finally, when DHEA was administered alone it increased the serum tumor necrosis factor-alpha (TNF-alpha ) levels when compared with controls; however, when metformin was administered together with DHEA, serum TNF-alpha levels were similar to controls. Metformin 156-165 tumor necrosis factor Mus musculus 209-218 20869956-10 2010 Both doses of UA lowered splenic IL-6 levels, whereas metformin increased IFN-gamma, IL-6 and TNF-alpha levels compared to the untreated diabetic mice. Metformin 54-63 tumor necrosis factor Mus musculus 94-103 35414608-12 2022 In addition, metformin alleviated the necroptosis of HK-2 cells stimulated by LPS and TNF-alpha, evidencing by a decrease in the expression of necroptosis markers p-RIPK1, p-RIPK3 and p-MLKL, and the inflammasome-related markers NLRP3 (NLR family pyrin domain containing 3), ASC (apoptosis-associated speck-like protein containing a CARD), caspase-1. Metformin 13-22 tumor necrosis factor Mus musculus 86-95 34570348-7 2021 Moreover, metformin treatment significantly downregulated the expression of pro-inflammatory associated genes (iNOS, H2-Aa, and TNF-alpha) in the corpus callosum, whereas expression of anti-inflammatory markers (Arg1, Mrc1, and IL10) was not promoted, compared to CPZ mice. Metformin 10-19 tumor necrosis factor Mus musculus 128-137 14499793-8 2003 The potential mechanisms of the action of metformin were the inhibition of hepatic tumor necrosis factor (TNF)alpha and several TNF-inducible responses, which are likely to promote hepatic steatosis and necrosis. Metformin 42-51 tumor necrosis factor Mus musculus 83-104 14499793-8 2003 The potential mechanisms of the action of metformin were the inhibition of hepatic tumor necrosis factor (TNF)alpha and several TNF-inducible responses, which are likely to promote hepatic steatosis and necrosis. Metformin 42-51 tumor necrosis factor Mus musculus 106-115 14499793-8 2003 The potential mechanisms of the action of metformin were the inhibition of hepatic tumor necrosis factor (TNF)alpha and several TNF-inducible responses, which are likely to promote hepatic steatosis and necrosis. Metformin 42-51 tumor necrosis factor Mus musculus 106-109 35156512-11 2022 Metformin also inhibited PDK1, HIF-1alpha expression, including downstream inflammatory mediators, HMGB1 and TNF-alpha. Metformin 0-9 tumor necrosis factor Mus musculus 109-118 33642112-11 2021 Metformin alleviated transcription and secretion of IL-1beta, Tumor Necrosis Factor-alpha, and Fibroblast Growth Factor 2, expression and nuclear translocation of C/EBPbeta in this model. Metformin 0-9 tumor necrosis factor Mus musculus 62-89 35145895-7 2022 Results: The results showed that all AA extracts (100, 200, and 400 mg/kg) and metformin (250 mg/kg) significantly reduced the serum levels of free fatty acids, TNF-alpha, IL-6, LDL/HDL ratio, and HOMA-IR in diabetic mice compared to untreated diabetic mice (p<0.0001). Metformin 79-88 tumor necrosis factor Mus musculus 161-170 35145895-8 2022 Notably, the 400 mg/kg dose of cold-water extract was more effective than metformin in reduction of TNF-alpha and IL-6 (p<0.01 and p<0.05, respectively). Metformin 74-83 tumor necrosis factor Mus musculus 100-109 33850550-8 2021 Furthermore, metformin treatment significantly inhibited the generation of inflammatory cytokines, including TNF-alpha and IL-1beta in db/db mice. Metformin 13-22 tumor necrosis factor Mus musculus 109-118 33947424-9 2021 These results suggest that metformin treatment has anti-inflammatory effects on lymphocytes via the inhibition of IL-17 and cytokines related to Th17 differentiation, such as IL-1beta, IL-6, and TNF-alpha. Metformin 27-36 tumor necrosis factor Mus musculus 195-204 33157041-8 2021 The beneficial effects of using both the naringenin and metformin along with the lower dose of doxorubicin were evident from the reduced dose-related body weight loss and increase in cytokines (TNF-alpha and IL-1beta) compared to a large dose of doxorubicin alone. Metformin 56-65 tumor necrosis factor Mus musculus 194-203 31902918-4 2020 In the present study, we found that metformin reduced the production of nitric oxide (NO) and the level of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Metformin 36-45 tumor necrosis factor Mus musculus 141-174 32189544-9 2020 Furthermore, 50mg/kg metformin markedly down-regulated the expression of proinflammatory cytokines (TNF-alpha and IL-1beta) and ER stress related genes (ATF4, ATF6, XBP1, Grp78 and CHOP) in rotenone-induced PD mice. Metformin 21-30 tumor necrosis factor Mus musculus 100-109